SLC5A2 and ulcer disease: Though no consensus was reached regarding the suitability of prescribing only certain types of SGLT2 inhibitors to patients with a history of diabetes‐related ulcers, participants agreed that canagliflozin should not be prescribed to patients with current or previous foot ulceration or amputation.